Assessment of cellular signaling pathways in cancer: Targeting aberrant kinases and phosphatases for personalized therapy

WangHao Mao

doi:10.54254/2753-8818/45/20240611

Abstract

Cancer is a group of diseases where cell proliferation is uncontrolled leading to formation of tumors which can spread to other parts of the body in a process called metastasis. With a mortality of about ten million deaths each year, cancer is responsible for one in six deaths which makes it one of the leading health problems worldwide. Because of this it is necessary for scientists to research cancer thoroughly to stop this problem as soon as possible. Cellular signaling pathways regulate cell proliferation, depending on the ligand that binds to cells it can lead to cell growth or apoptosis. So if a mutation happens in one of these pathways it can lead to serious problems such as the constant activation of the pathway causing uncontrolled cell growth and thus, cancer. In this review, I will focus on the aberrant kinases and phosphatases describing their pathways with detail and seeing how to target these mutations using combinatorial therapy with signal-transduction inhibitors to try to stop the pathogenesis of cancer. So far, there is no known cure for cancer and only some treatments in phase III are available. Trying to cure cancer is very complex, especially in cancer treatment as each patient may have genetic variations, the molecular profile of the tumor, and other unique biological characteristics, herein, personalized therapy based on different patients’ situation to increase treatment effectiveness while minimizing side effects. In this review, we intend to elucidate the significance of targeting aberrant kinases and phosphatases in the pathogenesis of cancer.

Keywords: cellular signaling pathways , kinases , phosphatases , combinatorial therapy

Article Information

Received: 10 October 2023

Published: 26 July 2024

DOI: https://doi.org/10.54254/2753-8818/45/20240611

Article Type: Research Article

Cite this article

Mao,W. (2024). Assessment of cellular signaling pathways in cancer: Targeting aberrant kinases and phosphatases for personalized therapy. Theoretical and Natural Science,45,215-220.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.45

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Sabaawy HE et al. (2021). JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis, 42(12):1411-1419. doi: 10.1093/carcin/bgab075

[2]Hua et al. (2021). Targeting Akt in cancer for precision therapy. Journal of Hematology and Oncology 14, 128. https://doi.org/10.1186/s13045-021-01137-8

[3]William H. Matsui. (2016). Cancer stem cell signaling pathways. Medicine 95:S1(e4765). http://dx.doi.org/10.1097/MD.0000000000004765

[4]A. De Luca et al. (2012). The RAS/RAF/MEK/ERK and the PI3K/AKT signaling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets, 16(Suppl.2):S17-S27. https://doi.org/10.1517/14728222.2011.639361

[5]Zou et al. (2020). mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell & Bioscience 10:31. https://doi.org/10.1186/s13578-020-00396-1

[6]Peng Y, Wang Y, Zhou C, Mei W, Zeng C. (2022). PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol. 12:819128. doi: 10.3389/fonc.2022.819128

[7]James C et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434(7037):1144-8. doi: 10.1038/nature03546

[8]Lippert E et al. (2006). The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood, 108(6):1865-7. doi: 10.1182/blood-2006-01-013540.

[9]Bellanger D, Jacquemin V, Pierron G, Stern MH. (2014). Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia, 28(2):417-9. doi: 10.1038/leu.2013.271

[10]Bousoik E, Montazeri Aliabadi H. (2018). “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway. Front Oncol, 8:287. doi: 10.3389/fonc.2018.00287

[11]Michiaki Kohno & Jacques Pouyssegur. (2006). Targeting the ERK signaling pathway in cancer therapy. Annals of Medicine, 38:3, 200-211. https://doi.org/10.1080/07853890600551037

[12]Libero Santarpia1 & Scott L. Lippman. (2012). Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy. Expert Opin Ther Targets, 16(1): 103–119. https://doi.org/10.1517/14728222.2011.645805

[13]Vaddi K, Sarlis NJ, Gupta V. (2012). “Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis”. Expert Opinion on Pharmacotherapy. 13 (16): 2397–407. doi:10.1517/14656566.2012.732998

[14]Shabbir M, Stuart R (March 2010). “Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside”. Expert Opinion on Investigational Drugs. 19 (3): 427–36. doi:10.1517/13543781003598862